Miriam Frankal

Mrs. Miriam Frankal

Deparrment of infectious diseases, Institute for Biomedicine, Sahlgrenska Academy, Gothenburg, Västra Götaland, Sweden
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in Journal of Clinical Virology
Verified
Journal Article
Open access
ÅMÅsa Mellgren
Åsa Mellgren
MFMiriam Frankal
Miriam Frankal
MKMarie Karlsson
Marie Karlsson
MLMartin Lagging
Martin Lagging
RWRune Wejstål
Rune Wejstål
HNHeléne Norder
Heléne Norder
Hepatitis E virus (HEV) genotype 3 is endemic in Europe. Superinfection with HEV in patients with underlying chronic liver disease can cause hepatic decompensation leading to increased morbidity and mortality. The prevalence of anti-HEV antibodies was investigated in 204 patients with chronic hepatitis C virus (HCV) infection and different stages of fibrosis. Sera were analyzed for anti-HEV IgG, IgM and HEV RNA. The median age of the patients was 55 years (IQR 40-62 years); 126 (62%) were men. Ninety-eight (48%) patients had a METAVIR fibrosis stage F2 or higher. The prevalence of anti-HEV IgG was 30% (62/204), which was significantly higher than among Swedish blood donors (17%, p<0.01). The prevalence of anti-HEV antibodies was associated with higher age (OR 1.08 (1.05-1.11); p<0.01). It was also higher for patients with a prior history of blood transfusion (48%) as compared to intravenous drug use (IDU; 26%) as the risk factor for acquisition of the HCV infection (OR 2.72 (1.2-6.19); p<0.02). The prevalence of anti-HEV IgG was also significantly higher in patients with significant fibrosis, i.e. ≥F2 (38%; OR 2.04 (1.11-3.76); p=0.02) and/or neoplasm (72%; OR 7.27 (2.46-21.44); p<0.01). When adjusted for age, the prevalence of anti-HEV antibodies was significantly higher in patients with previous or current malignant liver disease compared to blood donors. The lack of significant correlation between HCV and HEV infections indicate low level of transmission of HEV by IDU. HEV infections warrant more attention, especially in patients with preexisting liver disease.

25 September 2019 in Scandinavian Journal of Gastroenterology
Verified
Journal Article
Open access
MFMiriam Frankal
Miriam Frankal
HNHeléne Norder
Heléne Norder
MBMaria Bergström
Maria Bergström
PPPer-Ola Park
Per-Ola Park
MKMarie Karlsson
Marie Karlsson
ÅMÅsa Mellgren
Åsa Mellgren
Objective: Hepatitis E virus (HEV) genotype 3 is endemic in Northern Europe and despite a high seroprevalence of anti-HEV IgG antibodies among blood donors (≈17%), few clinical cases are notified in Sweden. Low awareness of hepatitis E and its possible symptoms may contribute to this discrepancy. The aim of this study was to investigate the prevalence of acute HEV infection among hospital admitted patients with abdominal pain and elevated liver enzymes. Materials and methods: During 2016–2017, 148 adult patients with serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > twice normal levels were prospectively enrolled at surgical wards at three Swedish hospitals. Serum samples were analyzed for HEV RNA as well as anti-HEV IgM and IgG, and medical records were reviewed. Results: Six (6/148, 4.1%) patients were HEV infected confirmed by detectable HEV RNA, but only one of these patients had detectable anti-HEV antibodies. Four of the HEV infected patients were diagnosed with gallstone-related disease: three with biliary pancreatitis and one with biliary colic. The remaining two were diagnosed with bowel obstruction and pancreatic malignancy. Four HEV strains were typed by sequencing to genotype 3. Conclusions: This study identified acute HEV3 infection in 4% of the patients with elevated liver enzymes admitted to a surgical ward. HEV infection was not the solitary disease leading to hospitalization, instead it was found to be associated with other surgical conditions such as gallstone-related disease including biliary pancreatitis. Additionally, HEV RNA might be the preferential diagnostic tool for detecting ongoing HEV infection.

11 November 2022 in Transplantation Direct
Verified
Journal Article
Open access
MFMiriam Frankal
Miriam Frankal
CSCatarina RN Skoglund
Catarina RN Skoglund
MCMaria Castedal
Maria Castedal
MLMartin Lagging
Martin Lagging
HNHeléne Norder
Heléne Norder
Export Background. Following exposure to hepatitis E virus (HEV), liver transplant (LT) recipients have an increased risk of developing chronic infection, which may rapidly progress to severe liver damage if not treated. The prevalence of HEV infection after LT is unclear and likely varies geographically. The aim of this study was to investigate the prevalence of acute and chronic HEV infection among LT recipients in an HEV endemic region. Methods. During 2013 to 2015, 109 of 152 prospectively enrolled patients listed for LT received a liver graft and completed the study protocol. They were evaluated for anti-HEV IgM, HEV IgG, and HEV RNA at the time of LT assessment and 3 and 12 mo post-LT. Medical records were reviewed. Results. Twelve (11%) LT recipients acquired markers of HEV infection during the study period. Seven patients (6%) had detectable HEV RNA, 1 before LT and 3 at the 3-mo and another 3 at the 12-mo follow-up post-LT. All resolved their infections without treatment and had undetectable HEV RNA at the succeeding follow-up. Another 5 (5%) patients developed anti-HEV antibodies without detectable HEV RNA as an indication of HEV infection during follow-up. Signs and symptoms of HEV infection were subtle‚ and none were diagnosed in routine clinical care. Conclusion. A substantial proportion of LT recipients in Sweden are at risk of acquiring HEV infection, both before and after LT. The results highlight the frequency of silent, spontaneously resolving HEV infections and do not support universal screening of LT recipients in Sweden, despite HEV being a potentially treatable infection.

15 September 2026 in Viruses
Verified
Journal Article
Open access
PDF file
KLKatarina Lund
Katarina Lund
MFMiriam Frankal
Miriam Frankal
AEAnders Eilard
Anders Eilard
JSJoakim Bedner Stenbäck
Joakim Bedner Stenbäck
EAErik Alestig
Erik Alestig
MLMagnus Lindh
Magnus Lindh
Hepatitis B surface antigen (HBsAg) loss is rarely achieved during long-term nucleos(t)ide analogue (NUC) therapy of chronic hepatitis B. Treatment discontinuation may lead to immune activation and HBsAg loss. In a prospective study, HBeAg-negative patients without liver cirrhosis stopped NUC therapy after a duration of at least 3 years. Follow-up for 2 years comprised monthly monitoring for the first six months. Twenty-five patients who discontinued therapy and six randomized controls who continued were included. After stopping NUC therapy, five patients (20%) developed an HBsAg seroclearance pattern, including four who lost HBsAg and one who achieved HBsAg below 1 IU/mL. Seven patients (28%) developed a state of immune control with persistently low HBV DNA and normal ALT. Six patients (24%) experienced severe flares requiring NUC re-initiation; all of them, including one with fulminant hepatitis necessitating liver transplantation, had detectable hepatitis B core-related antigen (HBcrAg) in serum at NUC discontinuation. The peak serum HBV DNA level strongly correlated with and preceded peak ALT. Thus, although half of the patients had favorable outcomes, there was a substantial risk of severe flares preceded by HBV DNA levels above 6 log10 IU/mL. Close monitoring, including frequent HBV DNA testing with rapid turnaround time, is therefore essential.